MSHS

CHLA Researchers Find That Length of Opioid Treatment for Hospitalized Infants Differs by Institution and Geography

Retrieved on: 
Tuesday, March 12, 2024
Other Health, Research, Pharmaceutical, Family, Consumer, Hospitals, Children, Science, Surgery, Baby, Maternity, Other Science, Health, JAMA Network Open, Ventricular septal defect, Risk, Infant, Prescription, MD, Methadone, MSHS, Hydromorphone, Morphine, Multimedia, Paper, Policy, Intubation, Fentanyl

View the full release here: https://www.businesswire.com/news/home/20240312681130/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240312681130/en/
    In a study published in JAMA Network Open, researchers at Children’s Hospital Los Angeles found the opioid treatment that critically ill, hospitalized infants received depended on their location.
  • The length of time the infants were prescribed opioids differed by geographic region across the U.S.— the Northeast, South, Midwest or West.
  • “Additionally, prolonged opioid exposure in high-risk hospitalized infants has been implicated in worsening neurodevelopmental outcomes,” Dr. Keane says.
  • During their hospital stay, 76% of infants were prescribed opioids such as fentanyl, morphine and hydromorphone, and about 8% received methadone.

Therabody Expands Investment in Science with $10 Million Research Pledge, Scientific Partnerships and Official Scientific Advisory Board

Retrieved on: 
Tuesday, March 12, 2024
Exercise, Learning, Men's Health, Beauty, MSHS, Sports medicine, Hot, NFL, Physical, Research, Innovation, The New York Times, The Pew Charitable Trusts, Partnership, Private practice, Education, Harvard University, Mexico national football team, Policy, Bodybuilding.com, MLS, American College, Physical fitness, Medicine, Fatigue, Harvard Medical School, Metabolism, Longevity, Advisory board, Sport, Public, FACP, ACSM, Senior, Athlete, MPH, FACSM, LOS, DPT, Premiership Rugby, Physical activity, Doctor of Philosophy, Physical therapy, Quicksilver, CSCS, MLB, Johns Hopkins University, Red Bull, Osteoporosis, Bangladesh Technical Education Board, NBA, Physician

LOS ANGELES, March 12, 2024 /PRNewswire/ -- Therabody, the leader in wellness technology, announced today the investment of more than $10M to fund initiatives that will continue to drive innovation and the scientific validation of their products. The company also announced the formalization of their Scientific Advisory Board and, significantly, a partnership with the American College of Sports Medicine (ACSM), the global research leader in the field of exercise, physical fitness and sports medicine.

Key Points: 
  • In an evolving regulatory landscape, Therabody believes that science is essential for leading the way forward as technology will transform healthcare over the next decade.
  • Their $10 million investment in scientific research will drive an integrated strategy for scientific leadership in the industry with funds put toward scientific and clinical research studies across beauty, wellness and athletic performance over the next several years.
  • Our Scientific Advisory Board, along with our significant investment in scientific research and partnerships, will ensure we remain at the forefront of our industry and dedicated to developing the most effective, scientifically validated products available today and in the future," said Monty Sharma, President and CEO of Therabody.
  • Therabody has completed 21 scientific studies to date with 26 currently in progress.

Therabody Expands Investment in Science with $10 Million Research Pledge, Scientific Partnerships and Official Scientific Advisory Board

Retrieved on: 
Tuesday, March 12, 2024
Exercise, Learning, Men's Health, Beauty, MSHS, Sports medicine, Hot, NFL, Physical, Research, Innovation, The New York Times, The Pew Charitable Trusts, Partnership, Private practice, Education, Harvard University, Mexico national football team, Policy, Bodybuilding.com, MLS, American College, Physical fitness, Medicine, Fatigue, Harvard Medical School, Metabolism, Longevity, Advisory board, Sport, Public, FACP, ACSM, Senior, Athlete, MPH, FACSM, LOS, DPT, Premiership Rugby, Physical activity, Doctor of Philosophy, Physical therapy, Quicksilver, CSCS, MLB, Johns Hopkins University, Red Bull, Osteoporosis, Bangladesh Technical Education Board, NBA, Physician

LOS ANGELES, March 12, 2024 /PRNewswire/ -- Therabody, the leader in wellness technology, announced today the investment of more than $10M to fund initiatives that will continue to drive innovation and the scientific validation of their products. The company also announced the formalization of their Scientific Advisory Board and, significantly, a partnership with the American College of Sports Medicine (ACSM), the global research leader in the field of exercise, physical fitness and sports medicine.

Key Points: 
  • In an evolving regulatory landscape, Therabody believes that science is essential for leading the way forward as technology will transform healthcare over the next decade.
  • Their $10 million investment in scientific research will drive an integrated strategy for scientific leadership in the industry with funds put toward scientific and clinical research studies across beauty, wellness and athletic performance over the next several years.
  • Our Scientific Advisory Board, along with our significant investment in scientific research and partnerships, will ensure we remain at the forefront of our industry and dedicated to developing the most effective, scientifically validated products available today and in the future," said Monty Sharma, President and CEO of Therabody.
  • Therabody has completed 21 scientific studies to date with 26 currently in progress.

Children’s Hospital Los Angeles Study Finds Many Kids With Sickle Cell Anemia Lack Preventative Care

Retrieved on: 
Wednesday, March 6, 2024
Health, Consumer, Other Health, Public Policy, Government, Pharmaceutical, Other Science, Research, Parenting, Children, Hospitals, Baby, Maternity, Science, Clinical Trials, Oxygen, Hospital, CHLA, Medicine, Infection, Multimedia, Hematology, Blood, Transport, Data collection, Anti-transglutaminase antibodies, Georgia State University, MSHS, Stroke, DSM-IV codes, Risk, Arthralgia, University, USC, Patient, MPH, Pediatrics, NCATS, Medicaid, CDC, Brain

Children with sickle cell anemia are vulnerable to serious infections and stroke, but many do not receive the preventative care that could help them stay healthier for longer, a Children’s Hospital Los Angeles study found.

Key Points: 
  • Children with sickle cell anemia are vulnerable to serious infections and stroke, but many do not receive the preventative care that could help them stay healthier for longer, a Children’s Hospital Los Angeles study found.
  • The researchers measured how many young children with sickle cell anemia received adequate preventative antibiotics to prevent infection and if children and adolescents with sickle cell anemia received annual brain ultrasounds to assess their stroke risk.
  • “What we found, unfortunately, was not what we’d hoped for,” says Ashaunta Anderson , MD, MPH, MSHS, Pediatrician at Children’s Hospital Los Angeles , who led the study.
  • Twice-daily doses of antibiotics, given consistently, can protect young children with sickle cell anemia from developing serious infections.

Emergency department boarding’s impact on patient care and clinician well-being

Retrieved on: 
Tuesday, November 28, 2023
Editorial, Delirium, Approximation error, Physician, Disease, Patient satisfaction, Health, Emergency, Quality, Perception, Nursing, Knowledge, Physical abuse, Safety, MPH, Patient, MSHS, Communication

ED boarding is associated with delayed and missed care, medication errors, delirium, higher morbidity and in-hospital mortality, and longer hospital length of stay as well as poor patient satisfaction.

Key Points: 
  • ED boarding is associated with delayed and missed care, medication errors, delirium, higher morbidity and in-hospital mortality, and longer hospital length of stay as well as poor patient satisfaction.
  • Semi-structured focus group interviews with a subsample of participants also were conducted to help interpret survey data and identify areas of improvement in boarding care.
  • A total of 39 clinicians participated in focus groups on the topic of boarding care and six themes were identified:
    Clinicians perceived that ED boarding leads to increased patient safety events.
  • Participants overwhelmingly felt that boarding patients received poorer care due to concerns of poor patient safety communication and a lack of training, resources and training.

GRAIL To Initiate REACH Study To Evaluate Clinical Impact Of GalleriⓇ Multi-Cancer Early Detection (MCED) Test Among The Medicare Population

Retrieved on: 
Monday, November 20, 2023
Science, Biotechnology, Research, Oncology, General Health, Health, Health Technology, Clinical Trials, MSHS, Woman, Health equity, Medicaid, Safety, Food, National Medical Association, NMA, Randomized controlled trial, Risk, Patient, Multimedia, ASCO, Friends of Cancer Research, Death, FDA, CMS, IDE, Friends, MD, Diagnosis, Partnership, 123rd, Medicare, PMA, Human, Pharmaceutical industry, Health insurance, Dietary supplement, Lancet, GRAIL, Cancer

With age being the most significant risk factor for cancer, Medicare beneficiaries face the highest unmet need for early cancer detection.

Key Points: 
  • With age being the most significant risk factor for cancer, Medicare beneficiaries face the highest unmet need for early cancer detection.
  • View the full release here: https://www.businesswire.com/news/home/20231120057874/en/
    The Galleri-Medicare study is a first-of-its-kind real-world study designed to further evaluate the clinical impact of the Galleri® multi-cancer early detection (MCED) test among Medicare beneficiaries, including racial and ethnic minorities, and seniors from historically under-served communities.
  • Medicare will cover the costs of Galleri and related and routine items and services for study participants.
  • “The Galleri-Medicare study demonstrates our commitment to provide broad, equitable access to early cancer detection that is representative of the U.S. population, including groups that are often under-represented in clinical research.

Target RWE Releases Important Updates on the Cirrhosis Quality Collaborative/TARGET-Liver Disease Partnership with the American Association for the Study of Liver Diseases

Retrieved on: 
Friday, November 10, 2023
MSHS, Calibration, Disease, Hepatology, Safety, Prevalence, Entrepreneurship, AASLD, CQC, Liver disease, Mortality, Chief Medical Officer (Ireland), Fatty liver disease, Patient, Liver, Cirrhosis, TARGET, Chronic liver disease, Partnership, Quality of life, LD, American Heart, RWE, American Heart Association, Pharmaceutical industry, Boston

DURHAM, N.C., Nov. 10, 2023 /PRNewswire/ -- Real-world evidence (RWE) leader Target RWE announced today that the CQC and TARGET-Liver Disease (LD) partnership with the American Association for the Study of Liver Diseases (AASLD) has enrolled approximately 75,000 patients.

Key Points: 
  • DURHAM, N.C., Nov. 10, 2023 /PRNewswire/ -- Real-world evidence (RWE) leader Target RWE announced today that the CQC and TARGET-Liver Disease (LD) partnership with the American Association for the Study of Liver Diseases (AASLD) has enrolled approximately 75,000 patients.
  • Target RWE has enrolled approximately 75,000+ patients under the TARGET-LD protocol to support AASLD/CQC.
  • The strategic partnership between Target RWE and AASLD is designed to fulfill the unmet need for a large, real-world registry of patients with chronic liver diseases.
  • "These liver diseases are growing in prevalence and are placing a tremendous burden on healthcare systems around the world.

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Island Ambulatory Surgery Center in Brooklyn, New York

Retrieved on: 
Thursday, November 9, 2023
Insurance, Standard of care, Urology, NYSE, Spine, Epidural steroid injection, Elective surgery, Physician, American Society of Interventional Pain Physicians, MD, American Board of Commissioners for Foreign Missions, Injection, MBA, Society, MSHS, Podiatry, MLSS, Mount Sinai Health System, Hospital, ESI, Safety, Pain management, American Board of Anesthesiology, Nursing, Anesthesiology

ROSELAND, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo® Epidural disposables into Island Ambulatory Surgery Center, a multi-specialty ambulatory surgery center based in Brooklyn, New York with a focus on pain management, orthopedics and spine care, urology, podiatry and plastic surgery. Island Ambulatory Surgery Center is affiliated with Mount Sinai Health System (MSHS), which operates 19 hospitals across New York.

Key Points: 
  • Island Ambulatory Surgery Center is affiliated with Mount Sinai Health System (MSHS), which operates 19 hospitals across New York.
  • Sales to Island Ambulatory Surgery Center represent the Company’s first foray into the ambulatory surgery center market—an addressable market of more than 9,000 centers across the U.S.
  • Dr. Leon Reyfman was one of a team of four doctors who completed eighteen cases using the CompuFlo Epidural system at Island Ambulatory Surgery Center, in which they reported 100% success.
  • Based on the favorable response to our technology, we remain confident that the CompuFlo Epidural system will ultimately become the standard of care in epidural analgesia.”

Point32Health and GRAIL Expand Pilot Access to Galleri® Multi-Cancer Early Detection Blood Test

Retrieved on: 
Thursday, September 28, 2023
Oncology, Medical Supplies, Health, Medical Devices, Other Health, Pharmaceutical, Biotechnology, Insurance, History of health care reform in the United States, Harvard Pilgrim Health Care, Cancer, Breast, Massachusetts General Hospital, Research, Prostate, MSHS, Trial of the century, Colon, Harvard Medical School, Lung, Tufts Health Plan, PCP, GRAIL, Patient, Risk, Mass, Mass General Brigham, Diagnosis, American Cancer Society, MPH, Health insurance, Medical imaging, MD, GRAIL (company), Medicine

“We are excited to expand our pilot to include Mass General Brigham by offering members this early detection screening test that could potentially save countless lives.”

Key Points: 
  • “We are excited to expand our pilot to include Mass General Brigham by offering members this early detection screening test that could potentially save countless lives.”
    Point32Health is the first commercial health plan in the U.S. to work with GRAIL to offer its Galleri screening test in addition to recommended cancer screenings.
  • The initial pilot program enabled access to Galleri at no cost for eligible Point32Health employees and Harvard Pilgrim Health Care members who purchase their insurance on the Maine health insurance marketplace.
  • As part of this pilot, Mass General Cancer Center’s Early Detection and Diagnostics Clinic will assess eligible participants for cancer risk and have the test available for those members at no cost.
  • In fact, about 71 percent of cancer deaths are from cancers that lack recommended early detection screening.

William Shrank, MD, Former Chief Medical Officer at Humana, to Join WW International, Inc. Board of Directors

Retrieved on: 
Thursday, August 3, 2023
Corporate Affairs, WW International, CMS, American Diabetes Association, Walgreens, University, Senior, Population health, Bio, U.S. Venture Partners, EVP, Policy, CVS, Health, Health equity, Research, Harvard University, MSHS, Science, Harvard Medical School, WW, Center for Medicare and Medicaid Innovation, University of Pittsburgh Medical Center, Andreessen Horowitz, MD, Clinical, UPMC, CVS Health, Nursing, Medical device, Hospital, Medicaid, Humana, Medicare, Retail, Strava, Brigham

Shrank to the board," said Thilo Semmelbauer, Chairman of the Board of WeightWatchers.

Key Points: 
  • Shrank to the board," said Thilo Semmelbauer, Chairman of the Board of WeightWatchers.
  • Shrank brings a wide range of healthcare experiences, including as a practicing physician and expertise in clinical outcomes for chronic conditions.
  • Shrank previously held the position of Chief Medical and Corporate Affairs Officer (July 2019-July 2021) during which time he oversaw government affairs.
  • Shrank served as Senior Vice President, Chief Scientific Officer, and Chief Medical Officer of Provider Innovation at CVS Health from 2013 to 2016.